Gilead Sciences, Inc.
GILD
$66.51
$0.350.53%
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Revenue | 7.11B | 7.05B | 6.60B | 6.35B | 7.39B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 7.11B | 7.05B | 6.60B | 6.35B | 7.39B |
| Cost of Revenue | 1.61B | 1.57B | 1.44B | 1.40B | 1.40B |
| Gross Profit | 5.50B | 5.49B | 5.16B | 4.95B | 5.99B |
| SG&A Expenses | 1.06B | 1.32B | 1.85B | 1.32B | 2.02B |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 4.11B | 4.34B | 4.69B | 4.17B | 5.00B |
| Operating Income | 3.00B | 2.72B | 1.91B | 2.18B | 2.39B |
| Income Before Tax | 1.65B | 2.32B | 1.59B | 1.30B | 2.03B |
| Income Tax Expenses | 237.00M | 146.00M | 549.00M | 316.00M | 398.00M |
| Earnings from Continuing Operations | 1.42B | 2.17B | 1.04B | 984.00M | 1.63B |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 12.00M | 8.00M | 6.00M | 26.00M | 7.00M |
| Net Income | 1.43B | 2.18B | 1.05B | 1.01B | 1.64B |
| EBIT | 3.00B | 2.72B | 1.91B | 2.18B | 2.39B |
| EBITDA | 3.69B | 3.40B | 2.59B | 2.82B | 2.91B |
| EPS Basic | 1.15 | 1.75 | 0.84 | 0.81 | 1.31 |
| Normalized Basic EPS | 1.44 | 1.30 | 0.89 | 1.04 | 1.11 |
| EPS Diluted | 1.13 | 1.73 | 0.83 | 0.80 | 1.30 |
| Normalized Diluted EPS | 1.43 | 1.29 | 0.88 | 1.03 | 1.10 |
| Average Basic Shares Outstanding | 1.25B | 1.25B | 1.25B | 1.25B | 1.25B |
| Average Diluted Shares Outstanding | 1.26B | 1.26B | 1.26B | 1.26B | 1.26B |
| Dividend Per Share | 0.75 | 0.75 | 0.75 | 0.75 | 0.73 |
| Payout Ratio | 65.99% | 43.72% | 90.33% | 95.94% | 55.79% |
